High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer

Basit Öğe Kaydı
dc.authoridKucuk, Ahmet/0000-0002-5361-364X
dc.authoridselek, ugur/0000-0001-8087-3140
dc.authoridTopkan, Erkan/0000-0001-8120-7123
dc.authoridOzturk, Duriye/0000-0002-3265-2797
dc.authorwosidKucuk, Ahmet/GQI-3022-2022
dc.authorwosidselek, ugur/O-5474-2014
dc.authorwosidTopkan, Erkan/AAG-2213-2021
dc.contributor.authorTopkan, Erkan
dc.contributor.authorKucuk, Ahmet
dc.contributor.authorOzkan, Emine Elif
dc.contributor.authorOzturk, Duriye
dc.contributor.authorBesen, Ali Ayberk
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorPehlivan, Berrin
dc.date.accessioned2024-05-19T14:46:01Z
dc.date.available2024-05-19T14:46:01Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground and objectives We explored the prognostic usefulness of the pan-immune-inflammation value (PIV) in patients with stage IIIB/C non-small-cell lung cancer (NSCLC) who underwent concurrent chemoradiotherapy (CCRT).Methods and patients For all patients, the PIV was calculated using platelet (P), monocyte (M), neutrophil (N), and lymphocyte (L) measures obtained on the first day of CCRT: PIV = P x M x N divided by L. Using receiver operating characteristic (ROC) curve analysis, we searched for the existence of an ideal cutoff that may partition patients into two groups with unique progression-free- (PFS) and overall survival (OS) results. The primary endpoint of this retrospective cohort research was to determine whether there were any significant relationships between pretreatment PIV measures and post-CCRT OS outcomes.Results The present research included a total of 807 stage IIIB/C NSCLC patients. According to ROC curve analysis, the ideal PIV cutoff was 516 [area under the curve (AUC): 67.7%; sensitivity: 66.4%; specificity: 66.1%], which divided the whole cohort into two: low PIV (L-PIV: PIV < 516; N = 436) and high PIV (H-PIV: PIV >= 516; N = 371). The comparisons between the PIV groups indicated that either the median PFS (9.2 vs. 13.4 months; P < 0.001) or OS (16.7 vs. 32.7 months; P < 0.001) durations in the H-PIV group were substantially inferior to their L-PIV counterpart. Apart from the H-PIV (P < 0.001), the N-3 nodal stage (P = 0.006), IIIC disease stage (P < 0.001), and receiving only one cycle of concurrent chemotherapy (P = 0.005) were also determined to be significant predictors of poor PFS (P < 0.05, for each) and OS (P < 0.05, for each) outcomes in univariate analysis. The multivariate analysis findings revealed that all four variables had independent negative impacts on PFS (P < 0.05, for each) and OS (P < 0.05, for each).Conclusions The findings of this hypothesis-generating retrospective analysis claimed that the novel PIV was an independent and steadfast predictor of PFS and OS in stage IIIB/C NSCLC patients.en_US
dc.identifier.doi10.1007/s12672-023-00851-8
dc.identifier.issn2730-6011
dc.identifier.issue1en_US
dc.identifier.pmid38091179en_US
dc.identifier.scopus2-s2.0-85179695454en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org10.1007/s12672-023-00851-8
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5420
dc.identifier.volume14en_US
dc.identifier.wosWOS:001123820000001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofDiscover Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectNon-Small-Cell Lung Canceren_US
dc.subjectInflammationen_US
dc.subjectBiological Markeren_US
dc.subjectPan-Immune-Inflammation Valueen_US
dc.subjectPrognosis Survivalen_US
dc.titleHigh pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu